LimmaTech Biologics AG

LimmaTech Biologics AG is a Swiss vaccine development company based in Schlieren. It focuses on developing innovative vaccines against antimicrobial-resistant pathogens, leveraging a proprietary self-adjuvanting and multi-antigen vaccine platform alongside disease-specific vaccine approaches. The company uses expertise in engineering E. coli to create complex carbohydrate and protein molecules for vaccine solutions, and states it is backed by leading investment funds and is expanding its pipeline.

LimmaTech Biologics AG is a company based in Schlieren, Switzerland. It has pioneered vaccine development technologies to build a pipeline of vaccine programs aimed at protecting against and preventing severe infections caused by pathogens resistant to antimicrobial treatments. The company leverages decades of experience in vaccine technologies and development, and uses expertise in engineering E. coli to create complex carbohydrate and protein molecules for vaccine solutions. It has developed a proprietary vaccine technology enabling design of vaccine candidates containing multiple immunogenic antigens that can be produced in a single scalable step, including engineering an E. coli strain to produce self-adjuvanting vaccine candidates. LimmaTech states it is led by a team with decades of vaccine development and manufacturing experience and is backed by leading investment funds, and that it is rapidly expanding its pipeline.

Vaccine developer combating antimicrobial resistance through proprietary E. coli-based multivalent vaccine technology.

1. 1LimmaTech Biologics AG | Homelmtbio.com
2. 2Company | LimmaTech Biologics AGlmtbio.com
3. 3Proprietary Vaccine Platform | LimmaTech Biologics AGlmtbio.com